Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
NBC Washington6d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Investors and patients will have to wait sometime for such products to launch, however, with Zealand Pharma's CEO and President Adam Steensberg telling CNBC that he expects Petrelintide to come to ...
pharmaphorum2d
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...
Zacks Investment Research on MSN6d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...